ESPERITE (ESP) : L1 Capital confirms its investment in Esperite and announces new funding for up to EUR 1.1 million before July 12, 2017
31 mai 2017 02h26 HE
|
Esperite N.V.
Zutphen, The Netherlands, 31 May 2017 As of today, EUR 940,000 out of the EUR 1.0 million tranche issued on March 8, 2017 have been converted into shares by European Select Growth Opportunities...
ESPERITE (ESP) Q1 consolidated revenue higher compared to budget
31 mai 2017 01h57 HE
|
Esperite N.V.
EBITDA improved compared to budget as a result of cost control Zutphen, the Netherlands - 31 May 2017 Market Update Q1 2017 The Q1 actual consolidated revenue of Esperite was higher compared to...
ESPERITE (ESP) has concluded new agreements with its note holders
31 mai 2017 01h17 HE
|
Esperite N.V.
Zutphen, the Netherlands - 31 May 2017 The unfortunate liquidation procedure against Genoma SA, ruled on May 4th 2017, for which an appeal is still pending, has triggered the obligation to repay...
ESPERITE N.V. convenes Annual General Meeting of Shareholders
23 mai 2017 09h43 HE
|
Esperite N.V.
Zutphen, The Netherlands - 23 May 2017 Esperite N.V. (Euronext: ESP, "Esperite") announces that it has convened its Annual General Meeting of Shareholders ("AGM") to be held on 4 July 2017 at...
ESPERITE (ESP) financial results for 2016 published
23 mai 2017 01h17 HE
|
Esperite N.V.
Zutphen, the Netherlands - 23 May 2017 ESPERITE N.V. (Euronext: ESP, "Esperite" or "the Group") has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report...
Esperite further delays publication of 2016 Annual Report
20 mai 2017 12h28 HE
|
Esperite N.V.
Zutphen, The Netherlands - 20 May 2017 Esperite N.V. (Euronext: ESP, the "Company" or "Esperite") announces that additional time is needed for the Company to publish its Annual Report for the...
Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court
19 mai 2017 07h19 HE
|
Esperite N.V.
Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with...
Esperite (ESP) confirme le développement positif de ses activités génétiques et annonce son intention de réclamer 5,2 millions de dommages-intérêts à Premaitha (NIPT)
15 mai 2017 04h17 HE
|
Esperite N.V.
Zutphen, les Pays-Bas, 15 mai 2017 La dernière action de Premaitha contre Genoma démontre sa tentative désespérée de cacher au public la situation financière de Premaitha. L'effet de leur action...
Esperite (ESP) - Esperite confirma el desarrollo positivo de sus actuales y futuras actividades en el mercado genético, y anuncia su intención de reclamar a Premaitha (NIPT) 5,2€M
15 mai 2017 04h17 HE
|
Esperite N.V.
Zutphen, Países Bajos, 15 mayo 2017 La última acción llevada a cabo por Premaitha contra Genoma demuestra una desesperada intención de encubrir la situación financiera de Premaitha. Los efectos de...
Esperite (ESP) - Il Gruppo conferma lo sviluppo positivo delle sue attività genetiche presenti e future e annuncia l'intenzione di richiedere 5.2 milioni di euro a Premaitha (NIPT) per danni
15 mai 2017 04h17 HE
|
Esperite N.V.
Zutphen, Paesi Bassi, 15 maggio 2017 Le ultime mosse di Premaitha contro Genoma, dimostrano il suo disperato tentativo di nascondere la situazione finanziaria di Premaitha stessa. L'effetto...